z-logo
open-access-imgOpen Access
Impact of Myalgic Encephalomyelitis on treatment of comorbidities: A lived experience
Author(s) -
Denise Lopez-Majano
Publication year - 2020
Publication title -
work
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.5
H-Index - 50
eISSN - 1875-9270
pISSN - 1051-9815
DOI - 10.3233/wor-203175
Subject(s) - encephalomyelitis , quality of life (healthcare) , medicine , chronic fatigue syndrome , disease , intensive care medicine , physical therapy , psychiatry , multiple sclerosis , pathology , nursing
Myalgic Encephalomyelitis (ME) is a complex, chronic, disabling, multi-system disease with no FDA-approved treatments. ME greatly impacts quality of life (QoL) with studies showing that people with ME often have worse quality of life than people with sickle cell anemia and cystic fibrosis, among other chronic diseases. People with ME frequently have comorbidities, which, if treated, could improve quality of life. However, the pervasive impact of ME makes treatment of comorbidities difficult. When trying to treat comorbidities it is therefore important for rehabilitation specialists to understand the impact of ME on day-to-day life in order to avoid treatment-related harms or exacerbation of ME symptoms. This article details the lived experience of one family in which both siblings have ME and comorbidities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom